Journal of clinical lipidology最新文献

{"title":"Two cases of late-onset lysosomal acid lipase deficiency with Achilles tendon thickening","authors":"Masahito Michikura PhD,&nbsp;Mariko Harada-Shiba MD, PhD,&nbsp;Kota Matsuki MD, PhD,&nbsp;Masatsune Ogura MD, PhD,&nbsp;Hideaki Morita MD, PhD","doi":"10.1016/j.jacl.2026.07.002","DOIUrl":"10.1016/j.jacl.2026.07.002","url":null,"abstract":"<div><div>Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal recessive lysosomal storage disease, classified into early-onset form and late-onset form. Late-onset LAL-D is characterized by dyslipidemia resembling familial hypercholesterolemia (FH), often leading to diagnostic challenges. Achilles tendon (AT) thickening is a well-known physical hallmark of FH, whereas it has not previously been reported in late-onset LAL-D. We report 2 cases of late-onset LAL-D in young women who exhibited AT thickening in ultrasonography. Both patients demonstrated markedly elevated low-density lipoprotein cholesterol levels and reduced lysosomal acid lipase activity, with pathogenic <em>lipase A lysosomal acid type</em> gene variants confirming the diagnosis of late-onset LAL-D. Ultrasonographic evaluation revealed AT thickening meeting the Japanese Atherosclerosis Society criteria for FH, with homogeneous internal tendon structures lacking hypoechoic areas or calcification. Notably, the internal echogenicity differed from that typically observed in FH, suggesting distinct underlying lipid deposition patterns. Late-onset LAL-D leads to intracellular accumulation of cholesterol esters and triglycerides within lysosomes, whereas FH is characterized by both intracellular lipid accumulation within macrophage foam cells and extracellular lipid deposition. These differences may account for the distinct ultrasonographic appearances of the AT observed in late-onset LAL-D compared with FH. This is the first report of AT thickening in patients with late-onset LAL-D. Our findings suggest that late-onset LAL-D should be included in the differential diagnosis when AT thickening is observed in patients with dyslipidemia. The combined assessment of AT ultrasonography and lipid profiles may enable accurate differentiation between late-onset LAL-D and FH, thereby facilitating early and appropriate diagnosis and management.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 2078-2084"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2026 Guideline on the Management of Dyslipidemia supports future quality measure compliance","authors":"Kaye-Eileen Willard MD, FNLA,&nbsp;Brian Hart JD","doi":"10.1016/j.jacl.2026.07.016","DOIUrl":"10.1016/j.jacl.2026.07.016","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 30-32"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148603463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term knowledge and screening outcomes following a gamified lipoprotein(a) curriculum for internal medicine residents at a large academic ambulatory practice","authors":"Andrew M. Cyr MD, MA,&nbsp;Ji-Cheng (Jason) Hsieh MD,&nbsp;Christian Leung MD,&nbsp;Rahul Rege MD,&nbsp;Spencer Weintraub MD,&nbsp;Lauren Block MD MPH","doi":"10.1016/j.jacl.2026.05.222","DOIUrl":"10.1016/j.jacl.2026.05.222","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 2093-2094"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia—Best evidence and practices aligned","authors":"Joseph J. Saseen PharmD, MNLA, FACC (Co-Editor),&nbsp;Daniel E. Soffer MD, MNLA, FAHA, FACP (Co-Editor)","doi":"10.1016/j.jacl.2026.04.023","DOIUrl":"10.1016/j.jacl.2026.04.023","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 1-3"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between non–high-density lipoprotein cholesterol levels and renal pathological changes in a population with apparently normal kidney function","authors":"Eri Ataka MD, PhD,&nbsp;Yuta Matsukuma MD, PhD,&nbsp;Kenji Ueki MD, PhD,&nbsp;Akihiro Tsuchimoto MD, PhD,&nbsp;Yasuhiro Okabe MD, PhD,&nbsp;Kosuke Masutani MD, PhD,&nbsp;Masafumi Nakamura MD, PhD,&nbsp;Takanari Kitazono MD, PhD,&nbsp;Toshiaki Nakano MD, PhD","doi":"10.1016/j.jacl.2026.07.013","DOIUrl":"10.1016/j.jacl.2026.07.013","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Dyslipidemia has been identified as a crucial factor for atherosclerotic disease. Recently, evidence for involvement of non–high-density lipoprotein cholesterol (nHDL-C) in atherosclerotic cardiovascular disease has been accumulating, and an association with the development of chronic kidney disease (CKD) has been reported. However, few studies have investigated the relationships between nHDL-C levels and renal pathological changes.</div></div><div><h3>OBJECTIVE</h3><div>To investigate the associations between nHDL-C levels and renal pathological changes in living kidney donors with apparently normal kidney function.</div></div><div><h3>METHODS</h3><div>In this cross-sectional study, we examined time-zero biopsy specimens from 345 living kidney donors and evaluated the relationships between serum nHDL-C levels and renal pathological changes, including arteriolar hyalinization, luminal stenosis of small-to-medium arteries, global glomerulosclerosis, and glomerular hypertrophy. We also evaluated the predictive performance of nHDL-C by calculating the net reclassification improvement (NRI) vs low-density lipoprotein cholesterol (LDL-C).</div></div><div><h3>RESULTS</h3><div>The distribution of nHDL-C levels was as follows: &lt;100 mg/dL in 15 patients (4%), 100 to 129 mg/dL in 84 patients (24%), 130 to 169 mg/dL in 160 patients (46%), and ≥170 mg/dL in 86 patients (25%). High nHDL-C was significantly associated with the prevalence of severe luminal stenosis (multivariable-adjusted odds ratio [OR] for nHDL-C ≥170 mg/dL vs nHDL-C 100 to 129 mg/dL: 3.62 [95% CI: 1.09-12.0]). Higher nHDL-C level was also associated with glomerular hypertrophy (OR per 10 nHDL-C increase: 1.19 [1.00-1.41]). In the NRI analyses, the model with nHDL-C added to the basic atherosclerotic factors exhibited better predictive performance for severe luminal stenosis than the model with LDL-C added to these factors (continuous NRI: 0.45 [0.13-0.78]).</div></div><div><h3>CONCLUSION</h3><div>High nHDL-C levels are potentially associated with renal pathological injury in subjects without CKD.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 1788-1798"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148603499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of clinical scoring systems, laboratory, and genetic testing for appropriate classification of patients with severe hypertriglyceridemia in a Latin American cohort","authors":"Gregorio Fariña BS,&nbsp;Amira Sleiman MD,&nbsp;Rodrigo Alonso MD, PhD,&nbsp;Jonhayro Gutiérrez Restrepo MD,&nbsp;Camila Spagnuolo BS,&nbsp;Natalia Agudelo Valencia MD,&nbsp;Josefina González Moore MD,&nbsp;Diana Sánchez Peñarete MD,&nbsp;Nadia Schvarzman BS,&nbsp;Alejandro Román González MD,&nbsp;Claudia Monsalve MD,&nbsp;Ada Cuevas MD, MSc,&nbsp;Luciana Yenny Melnik MD,&nbsp;Pablo Alberto Castaño Ceballos MD,&nbsp;Augusto Lavalle Cobo MD,&nbsp;Eduardo Osvaldo Esteban MD,&nbsp;Daniel Aimone MD,&nbsp;Alejandro Castellanos Pinedo MD,&nbsp;Juan Patricio Nogueira MD, PhD,&nbsp;Gabriela Berg PhD","doi":"10.1016/j.jacl.2026.07.012","DOIUrl":"10.1016/j.jacl.2026.07.012","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by severe hypertriglyceridemia (sHTG) due to variants in canonical genes (<em>LPL</em> [lipoprotein lipase], <em>APOA5</em>, <em>APOC2</em>, <em>GPIHBP1</em>, and <em>LMF1</em>); its genotype distribution in Latin America remains scarcely reported. Given limited access to genetic testing and frequent negative results in clinically consistent cases, clinical scores and lipid ratios have been proposed to predict FCS.</div></div><div><h3>OBJECTIVE</h3><div>This study aimed to outline the genetic, clinical, and biochemical characteristics, as well as the performance of scoring systems, in a Latin American cohort of patients with sHTG.</div></div><div><h3>METHODS</h3><div>Genetic, clinical, and biochemical data were obtained in 77 individuals with sHTG (TG &gt;10 mmol/L), including 28 genetically diagnosed FCS and 49 multifactorial chylomicronemia syndrome (MCS). Triglyceride/total cholesterol (TG/TC), TG/apolipoprotein B (apoB) ratios, and Moulin and North American Familial Chylomicronemia Score (NAFCS) scores were calculated.</div></div><div><h3>RESULTS</h3><div>Among patients with FCS, non-<em>LPL</em> monogenic defects were present in 64% of patients (n = 18), with variants in <em>APOA5</em> (n = 11), <em>GPIHBP1</em> (n = 3), <em>APOC2</em> (n = 2), and <em>LMF1</em> (n = 2). Diagnosis was frequently delayed, and body mass index overlapped across groups. Biochemical biomarkers showed good diagnostic performance, with AUCs of 0.767 (95% CI: 0.640-0.876; <em>P</em> &lt; 0.0001) for TG/TC and 0.790 (95% CI: 0.651-0.906; <em>P</em> &lt; 0.0001) for TG/apoB. Moulin score showed high sensitivity (91.3%), whereas NAFCS score showed high specificity (90.9%).</div></div><div><h3>CONCLUSION</h3><div>This large multicenter Latin American study of sHTG reveals a distinct genetic landscape from other regions. It also supports the performance of clinical scores and the discriminatory accuracy of biochemical indices.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 1870-1880"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality, cardiovascular, and hepatic decompensation outcomes of bempedoic acid in patients with cirrhosis: A multi-institutional study","authors":"Mohamad Mahdi Osman DO,&nbsp;Talal Massad MD,&nbsp;Omar T. Sims PhD,&nbsp;Dian J. Chiang MD","doi":"10.1016/j.jacl.2026.06.026","DOIUrl":"10.1016/j.jacl.2026.06.026","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Data on bempedoic acid in cirrhosis are limited.</div></div><div><h3>OBJECTIVE</h3><div>To evaluate associations between bempedoic acid use and clinical outcomes in adults with cirrhosis.</div></div><div><h3>METHODS</h3><div>We conducted a retrospective TriNetX cohort study comparing adults with cirrhosis receiving versus not receiving bempedoic acid. Patients with end-stage renal disease or prior liver transplantation were excluded. Propensity score matching was performed 1:1 using demographic, clinical, medication, and laboratory variables. Outcomes were mortality, hospitalization, hepatic decompensation, and major adverse cardiovascular events.</div></div><div><h3>RESULTS</h3><div>After matching, 325 pairs were analyzed. Bempedoic acid use was associated with lower all-cause mortality (hazard ratio [HR], 0.28; 95% CI, 0.17-0.45; <em>P</em> &lt; 0.001) and all-cause hospitalization (HR, 0.52; 95% CI, 0.40-0.68; <em>P</em> &lt; 0.001). No significant differences were observed in hepatic decompensation (HR, 0.96; 95% CI, 0.62-1.50; <em>P</em> = .86) or MACE (HR, 0.84; 95% CI, 0.50-1.39; <em>P</em> = .49) did not differ.</div></div><div><h3>CONCLUSION</h3><div>Bempedoic acid was associated with lower mortality and hospitalization without increased hepatic decompensation. Residual confounding and immortal time bias limit causal interpretation.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 2041-2045"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148549319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected impact of 2026 ACC/AHA/Multisociety Dyslipidemia Guideline on lipid-lowering therapy eligibility based on Class 1 and 2a recommendations","authors":"Sameer A. Sidiq MD,&nbsp;Geoffrey Y. Zhang BS,&nbsp;Dmitry Abramov MD,&nbsp;Alexander C. Razavi MD PhD,&nbsp;Vijay Nambi MD PhD,&nbsp;Xiaoming Jia MD,&nbsp;Salim S. Virani MD PhD,&nbsp;Christie M. Ballantyne MD,&nbsp;Roger S. Blumenthal MD,&nbsp;Abdul Mannan Khan Minhas MD","doi":"10.1016/j.jacl.2026.07.008","DOIUrl":"10.1016/j.jacl.2026.07.008","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>The 2026 American College of Cardiology/American Heart Association/Multisociety Dyslipidemia Guideline introduced pivotal changes to lipid-lowering therapy (LLT) eligibility compared with the 2018 Guideline.</div></div><div><h3>OBJECTIVE</h3><div>We aimed to compare eligibility for Class 1 and 2a LLT indications in the United States between the 2018 and 2026 Dyslipidemia Guidelines.</div></div><div><h3>METHODS</h3><div>We utilized National Health and Nutrition Examination Survey 2011-2018 datato evaluate LLT eligibility among participants aged ≥20 years, excluding pregnant women. Population weighted estimates were generated by indication and by demographic characteristic.</div></div><div><h3>RESULTS</h3><div>Under the 2026 Guideline, 102.9 million adults (46.8%, 95% CI: 45.0-48.6) would be eligible for LLT, including 65.3 million (29.7%, 95% CI: 28.0-31.4) with a Class 1 indication and 37.6 million (17.1%, 95% CI: 15.8-18.4) with a Class 2a indication, compared with 65.3 million adults (29.7%, 95% CI: 28.1-31.3) under the 2018 Guideline, including 60.2 million (27.4%, 95% CI: 25.8-28.9) and 5.1 million (2.3%, 95% CI: 2.0-2.7), respectively. The increase in eligibility was primarily driven by 2 additional Class 2a indications introduced in the 2026 Guideline: individuals with borderline Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) risk (previously classified as Class 2b) and adults aged 30 to 59 years with low PREVENT risk but elevated low-density lipoprotein cholesterol or elevated 30-year atherosclerotic cardiovascular disease risk.</div></div><div><h3>CONCLUSION</h3><div>Future studies should assess whether expanded eligibility improves LLT use and cardiovascular outcomes.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 2046-2050"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of PREVENT-ASCVD vs pooled cohort equations on statin eligibility across demographic groups: Insights from the NIH All of Us Research Program","authors":"Cammie Young BA,&nbsp;Frances Golden MD, MPH,&nbsp;Wenjun Fan MD, PhD,&nbsp;Nathan D. Wong PhD, MPH","doi":"10.1016/j.jacl.2026.07.003","DOIUrl":"10.1016/j.jacl.2026.07.003","url":null,"abstract":"<div><div>We compared the predicting risk of cardiovascular EVENTS-atherosclerotic cardiovascular disease (PREVENT-ASCVD) risk equation with the pooled cohort equation (PCE) for estimating statin eligibility across demographic subgroups in the All of Us Research Program in patients without ASCVD, heart failure, diabetes, or lipid-lowering therapy. Statin eligibility was defined as a 10-year ASCVD risk for PREVENT-ASCVD ≥5% and PCE ≥7.5%. Eligibility estimates were compared across age, sex, and race/ethnicity, and by quintile of polysocial risk score (PsRS). Among 25,188 participants, overall statin eligibility was 23.1% under PREVENT-ASCVD compared with 28.0% under PCE (Δ = 4.9%, <em>P</em> &lt; 0.001). The largest differences were among participants aged 60 to 69 years and among Black participants. Among those with PsRS data (n = 6213), PREVENT-ASCVD estimated lower statin eligibility than PCE across all quintiles (<em>P</em> &lt; 0.05). Differences in statin eligibility between PREVENT-ASCVD and PCE persist even when applying guideline-recommended thresholds, highlighting the importance of incorporating additional risk-enhancing factors beyond those included in either equation to better inform primary prevention decisions.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 2062-2068"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) and aortic diseases: Epidemiological evidence from observation to causation","authors":"Dexiang Xia MD,&nbsp;Lei Zhang MD, PhD,&nbsp;Junjie Fang MD,&nbsp;Wentao Hu MD,&nbsp;Maohua Li PhD,&nbsp;Yunfan Chen MD,&nbsp;Chang Shu MD, PhD,&nbsp;Jiehua Li MD, PhD,&nbsp;Xin Li MD, PhD","doi":"10.1016/j.jacl.2026.07.014","DOIUrl":"10.1016/j.jacl.2026.07.014","url":null,"abstract":"<div><h3>BACKGROUND</h3><div>Aortic aneurysm and dissection (AA/AD) are life-threatening vascular diseases with high mortality, yet no effective drugs to delay progression. Lipoprotein(a) [Lp(a)] is genetically determined and associated with atherosclerotic disease, but high-quality evidence on its causal role in AA/AD remains limited.</div></div><div><h3>OBJECTIVE</h3><div>To investigate the association between Lp(a) and AA/AD and assess potential causal relationships with major aortic disease subtypes.</div></div><div><h3>METHODS</h3><div>A prospective cohort of 312,332 UK Biobank participants was analyzed. Kaplan–Meier curves, Cox regression, and Fine–Gray competing-risk models assessed associations between Lp(a) and incident AA/AD. Two-sample Mendelian randomization (MR) analyses evaluated the potential causal effects of Lp(a) on AA, abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), and AD.</div></div><div><h3>RESULTS</h3><div>During a median follow-up of 16.5 years, 3122 AA/AD events occurred. Elevated Lp(a) independently predicted AA/AD with a dose–response relationship (hazard ratio [HR] = 1.40 for &gt;180 vs &lt;50 nmol/L; HR = 1.15 per 75 nmol/L increment). Competing-risk analyses yielded consistent results. MR analyses supported a causal association between Lp(a) and AA (odds ratio [OR] = 1.31, 95% CI: 1.08-1.62) and AAA (OR = 1.80, 95% CI: 1.37-2.37), whereas MR analyses did not provide sufficient evidence for causal associations with TAA or AD.</div></div><div><h3>CONCLUSION</h3><div>Lp(a) may serve as a promising biomarker for risk assessment and stratification in aortic disease. However, the MR analysis for AD was limited by low statistical power, and the clinical utility of Lp(a) measurement requires further investigation.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"20 9","pages":"Pages 1978-1987"},"PeriodicalIF":6.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}